Detection of tumor-derived genetic and epigenetic alterations in plasma and serum may have a profound impact on the noninvasive diagnosis of cancers among high-risk populations (1) (2) (3) . Chronic hepatitis infection and cirrhosis are well-documented risk factors for hepatocellular carcinoma (HCC) (4 ) . However, patients with chronic hepatitis/cirrhosis may develop HCC only after many years. One long-sought goal in this field, therefore, has been the development of sensitive, specific, and noninvasive blood tests for the early detection and monitoring of HCC (5 ) . A well-established conventional marker for HCC, serum ␣-fetoprotein (AFP), has limitations for cancer screening because high-risk individuals with AFP concentrations within the reference interval may have already developed HCC at an advanced stage (6, 7 ) . Hypermethylation of p16, a cyclin-dependent kinase inhibitor gene that regulates cell cycling, has been found frequently in human cancers, including HCC (3, 8 ) . Using methylation-specific PCR (MSP), we analyzed p16 promoter methylation status in 100 plasma and serum samples from HCC patients, controls with chronic hepatitis/ cirrhosis, and healthy subjects. Of particular diagnostic interest, we investigated the relationship of p16 methylation status and the serum AFP concentration.
With informed consent and ethics approval, peripheral blood samples were obtained from 45 HCC patients before surgical resection, 35 non-HCC patients with chronic hepatitis/cirrhosis, and 20 healthy volunteers. The diagnosis of HCC was confirmed histopathologically in liver biopsy and was based on serum AFP concentration Ն500 g/L, ultrasound examination with computed tomography, or hepatic angiography as appropriate. Tumor specimens were collected from the HCC patients after surgery, and DNA was extracted using a QIAamp Tissue Kit (Qiagen). Peripheral blood samples were centrifuged at 3000g, and plasma and serum samples were collected from EDTA-containing and plain tubes, respectively. DNA was extracted from 400 L of plasma or serum by a QIAamp Blood Kit (Qiagen).
Bisulfite modification of DNA was conducted using the CpGenome DNA Modification Kit (Intergen). Bisulfitetreated DNA was amplified using primers for the methylated p16 sequence (3, 9 ) . The sense and antisense primers for the methylated p16 sequence were 5Ј-TTA TTA GAG GGT GGG GCG GAT CGC-3Ј and 5Ј-GAC CCC GAA CCG CGA CCG TAA-3Ј, respectively. All bisulfiteconverted DNA samples were also amplified using primers for the unmethylated p16 sequence. The sense and antisense primers for the unmethylated p16 sequence were 5Ј-TTA TTA GAG GGT GGG GTG GAT TGT-3Ј and 5Ј-CAA CCC CAA ACC ACA ACC ATA A-3Ј, respectively. PCR was conducted using the GeneAmp DNA Amplification Reagent Kit and AmpliTaq Gold polymerase (Perkin-Elmer). Using 35 cycles for tumor DNA and 55 cycles for circulating DNA, the thermal profile consisted of an initial denaturation step of 95°C for 12 min followed by repetitions of 95°C for 45 s, 60°C for 45 s, and 72°C for 60 s, with a final extension step of 72°C for 10 min (3, 10 ) . PCR products were loaded onto 2% agarose gel and stained with ethidium bromide. Each sample was analyzed in duplicate, in parallel with a methylated cell line (see below), unmethylated controls, and multiple negative water blanks. The identity of the PCR product for the methylated p16 sequence was confirmed by nonradioactive Southern blot analysis (11 ) . The probe sequence designed to hybridize to the methylated p16 sequence was 5Ј-GAG TAG TAT GGA GTT TTC GGT TGA TTG GTT G-3Ј.
A plasmacytoma-derived cell line, HS-Sultan (CRL-1484; American Type Culture Collection), previously shown to have p16 methylation by Southern blot analysis (12 ) , was used as a methylated control for MSP. To determine the sensitivity of MSP, HS-Sultan DNA was serially diluted in water, mixed with normal peripheral blood cell DNA, bisulfite-converted, and then amplified by MSP. The lower detection limit for the methylated p16 allele was 50 pg of HS-Sultan DNA in 1000 ng of buffy coat DNA from a healthy volunteer.
Preoperative serum AFP concentrations were measured by a two-site sandwich immunoassay (Automated Chemiluminescence System 180; Bayer Diagnostics) and were correlated with the p16 methylation status in plasma or serum from the 45 HCC patients and the 35 non-HCC patients with chronic hepatitis/cirrhosis. The relationship between the p16 methylation status and the serum AFP concentration was assessed using ROC curves and the Fisher exact test.
We demonstrated the presence of methylated p16 sequences in plasma or serum from 80% (24 of 30) of HCC patients with tumoral p16 methylation ( Table 1 ). Among the 30 HCC patients with tumoral p16 methylation, we found a significant association between the p16 methylation status in circulating DNA and the preoperative serum AFP concentration. A serum AFP concentration of 45 g/L was found to give the best discrimination between HCC patients with or without p16 methylation in circulating DNA (MedCalc 5.0). Thus, all 16 cases (100%) with serum AFP concentrations Ͼ45 g/L showed p16 methylation in circulating DNA (Fig. 1 ), whereas only 57% (8 of 14) of cases with AFP concentrations Յ45 g/L (range, 4 -45 g/L) had p16 methylation (specificity ϭ 100%; sensitivity ϭ 67%; MedCalc 5.0). The difference in the proportion of HCC patients with circulating methylated p16 sequences between the two groups with higher or lower AFP concentrations was statistically significant (Fisher exact test, P ϭ 0.005). None of the 20 healthy volunteers studied had p16 methylation in plasma or serum. None of the 35 non-HCC patients with chronic hepatitis/cirrhosis had p16 methylation in circulating DNA. Four patients of the latter control group had serum AFP concentrations Ͼ45 g/L, whereas the remaining 31 had AFP concentrations Յ45 g/L.
Clinically, serum AFP concentration alone cannot reliably differentiate HCC from benign liver diseases, especially when the concentration is Ͻ500 g/L. In this study, only 29% (13 of 45) of HCC patients had serum AFP concentrations Ն500 g/L (Table 1 ). For the remaining Twenty-four patients showed p16 methylation in circulating DNA, whereas 6 patients were methylation-negative. A serum AFP concentration of 45 g/L is indicated by the dashed line. All of the patients with AFP concentrations Ͼ45 g/L had circulating methylated p16 sequences. F, methylation-positive and AFP Ͼ45 g/L; E, methylation-positive and AFP Յ45 g/L; ‚, methylationnegative and AFP Յ45 g/L.
71%, diagnostic confirmation based on ultrasonography and angiography was required. Of diagnostic relevance, the application of the p16 methylation marker enabled us to detect circulating tumor DNA in 80% of HCC patients with tumoral p16 methylation. Aberrant p16 methylation may thus serve as a valuable molecular marker for the noninvasive and early diagnosis of HCC among high-risk populations. Indeed, the peripheral blood MSP assay for p16 could identify 53% (24 of 45) of HCC patients, including those who were not detectable by AFP screening alone. The combination of the MSP assay with the AFP test further improved the rate of HCC detection to 62% (28 of 45). Therefore, addition of the p16 methylation marker, detectable in plasma or serum from patients with well-differentiated or early-stage tumors (3 ), would possibly permit early detection of HCC and hence earlier treatment among high-risk populations. Our data suggest the diagnostic implications of p16 methylation for the noninvasive diagnosis of cancer with potentially higher sensitivity and specificity. For disease monitoring, an increased serum AFP concentration (Ͼ10 g/L) is generally applied as one of the useful criteria. However, clinical metastasis and recurrence might also be present in HCC patients with serum AFP concentrations within the reference interval. We currently are studying the usefulness of the peripheral blood MSP analysis for monitoring minimal residual tumor or micrometastasis, especially among HCC patients with serum AFP concentrations within the reference range during clinical follow-up.
Of biological interest, we report for the first time a statistically significant correlation between the p16 methylation status in circulating DNA and the preoperative serum AFP concentration. Among the HCC patients with tumoral p16 methylation, 100% of the cases with serum AFP concentrations Ͼ45 g/L had circulating methylated p16 sequences, whereas only 57% of patients with AFP concentrations Յ45 g/L had p16 methylation. None of the 35 non-HCC patients with chronic hepatitis/cirrhosis, regardless of their AFP concentrations, had p16 methylation in circulating DNA. Although the biological basis of this relationship remains unclear at present, our findings may stimulate further investigations into the correlations of conventional tumor markers with the new generation of molecular markers based on DNA analysis in plasma and serum. All newborns in the United States are screened by statesponsored programs for congenital hypothyroidism. Traditionally, this has involved an initial screen for thyroxine (T 4 ), followed by testing thyrotropin (TSH) concentrations of infants with low T 4 values. This algorithm or an alternative whereby only TSH is assayed does not detect all hypothyroid newborns (1 ) . A simultaneous assay that measures both T 4 and TSH would be preferred for screening. Luminex MultiAnalyte Profiling Technology (Lab-MAP) was used to develop an immunoassay that measures T 4 and TSH simultaneously from a single blood-spot sample. The method uses a mixture of two distinct sets of uniquely fluorescent microspheres, which are identified by distinct red and orange fluorescent dyes by the Luminex 100 flow analyzer (2 ) . Quantification is accomplished with a green fluorescent reporter molecule. At present, 100 distinct sets of fluorescent microspheres are available, permitting the simultaneous measurement of as many as 100 different analytes.
Simultaneous Measurement of Thyroxine and Thyrotropin from Newborn Dried Blood-Spot Specimens Using a Multiplexed Fluorescent
Uniquely, LabMAP provides the ability to combine
